<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049852</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-CS101</org_study_id>
    <nct_id>NCT03049852</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium</brief_title>
  <acronym>Pterygium</acronym>
  <official_title>A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cloudbreak Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cloudbreak Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. CBT-001 administered three times daily (TID) for 4 weeks has an acceptable safety
           profile when used in pterygium patients

        2. CBT-001 administered TID for 4 weeks is more effective than the vehicle in reducing
           pterygium vascularity and inhibiting pterygium lesion growth

        3. CBT-001 administered as topical ocular dosing displays negligible systemic drug
           exposure
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pterygium Vascularity assessed using the Pterygium Hyperemia Grading Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Pterygium vascularity will be graded by analysis of digital images of the eyes using Pterygium Hyperemia Grading Scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>CBT-001 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study administered three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in the study administered three times daily (TID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-001</intervention_name>
    <description>One drop in the study administered three times daily (TID)</description>
    <arm_group_label>CBT-001 Ophthalmic Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>One drop in the study administered three times daily (TID)</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale â‰¥ 3)

        Exclusion Criteria:

          -  Active ocular disease, corneal abnormalities other than pterygium, active ocular
             infection, or any ocular pathology unrelated to pterygium in either eye that could
             affect the assessment of the pterygium

          -  History of ocular herpes disease in either eye

          -  Any ocular surgical procedure within the last 3 months

          -  Female patients who are pregnant, nursing, or planning a pregnancy during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinsong Ni, Ph.D.</last_name>
    <email>ni_jinsong@cloudbreaktherapeutics.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>February 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
